title: Making genuine progress against metastatic breast cancer.
authors.affiliation: Duke University and the Duke Cancer Institute, 2424 Erwin Rd, Suite 205, Durham, NC 27705, USA. gary.lyman@duke.edu
authors.forename: Gary H
authors.initials: GH
authors.lastname: Lyman
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
authors.forename: Aman U
authors.initials: AU
authors.lastname: Buzdar
authors.forename: Ralph
authors.initials: R
authors.lastname: D'Agostino
authors.forename: Paul A
authors.initials: PA
authors.lastname: Ellis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D017277:Drug Approval; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D015996:Survival Rate; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab